The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1124
February 18, 2002
View Complete Issue         Table of Contents 2019 
Almotriptan (Axert) and Frovatriptan (Frova) for Migraine
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Almotriptan (Axert) and Frovatriptan (Frova) for Migraine
February 18, 2002 (Issue: 1124)
Almotriptan (Axert - Pharmacia), and Frovatriptan (Frova - Elan) have been approved by the FDA for oral treatment of migraine headache (Drugs of Choice from The Medical Letter 2001, page 131.).
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Almotriptan (Axert) and Frovatriptan (Frova) for Migraine
Article code: 1124c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.